Allecra and Acino Ink Pact for Allecra's Novel Antibiotic Exblifep

Allecra Therapeutics and Acino declared the signing of a licensing agreement in which Acino acquire privileges to popularize Allecra's anti-microbial medication Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance, which incorporates Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, from 12 June 2024. Additionally, a supply agreement between the two businesses stipulates that Allecra will supply the cefepime/enmetazobactam finished product in the aforementioned regions.

“Acino has established itself as a leader in South Africa and the GCC region. They are an ideal partner to support us as we build towards commercialisation of Exblifep following our regulatory approvals in the US and EU,” stated Andreas Kranzusch, chief financial officer and managing director at Allecra Therapeutics. “This agreement reflects the understanding that there remains a significant global need to address the dangerous increase of resistance to standard-of-care antibiotics, and we look forward to working with Acino to address this.”

“At Acino, we are dedicated to providing novel healthcare solutions to physicians and patients, aiming to alleviate the health burden in emerging markets. We are incredibly excited to partner with Allecra to offer access to this innovative product in two key geographic regions and, potentially, beyond,” said Andrew Bird, CEO (ai) at Acino. “We are committed to expediting the registration process in these designated markets to ensure hospitals’ swift access to Exblifep as they continue to fight against high-risk infectious diseases in patients.”